Medical Marijuana Use in Oncology: A Review | History of Medicine | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Zuardi  AW.  History of cannabis as a medicine: a review.  Rev Bras Psiquiatr. 2006;28(2):153-157.PubMedGoogle ScholarCrossref
2.
Narconon International. History of marijuana use. http://www.narconon.org/drug-information/marijuana-history.html. Accessed July 2, 2015.
3.
Bonnie  RJ, Whitebread  CH.  The forbidden fruit and the tree of knowledge: an inquiry into the legal history of American marijuana prohibition.  Virginia Law Rev. 1970:971-1203.Google Scholar
4.
Zeese  KB.  History of medical marijuana policy in US.  Int J Drug Policy. 1999;10(4):319-328.Google ScholarCrossref
5.
Nelson  B.  Medical marijuana: hints of headway? despite a conflicted regulatory landscape, support for medical marijuana is growing amid increasing evidence of potential benefits.  Cancer Cytopathol. 2015;123(2):67-68.PubMedGoogle ScholarCrossref
6.
Lee  M.  Smoke Signals: A Social History of Marijuana—Medical, Recreational, Scientific. New York, NY: Scribner; 2012.
7.
Martin  A, Rashidian  N.  A New Leaf: The End of Cannabis Prohibition. New York, NY: New Press; 2014.
8.
Stebbins  S, Frohlich  TC, Sauter  MB. The next 11 states to legalize marijuana. USA Today. August 19, 2015. http://www.usatoday.com/story/money/business/2015/08/18/24-7-wall-st-marijuana/31834875/. Accessed September 3, 2015.
9.
Johannigman  S, Eschiti  V.  Medical use of marijuana in palliative care.  Clin J Oncol Nurs. 2013;17(4):360-362.PubMedGoogle ScholarCrossref
10.
Miron  J, Waldock  K.  The Budgetary Impact of Ending Drug Prohibition. Washington, DC: Cato Institute; 2010.
11.
Imam  J. Pot money changing hearts in Washington. CNN. July 11, 2015. http://www.cnn.com/2015/07/10/us/washington-marijuana-70-million-tax-dollars/. Accessed December 10, 2015.
12.
Charuvastra  A, Friedmann  PD, Stein  MD.  Physician attitudes regarding the prescription of medical marijuana.  J Addict Dis. 2005;24(3):87-93.PubMedGoogle ScholarCrossref
13.
Adler  JN, Colbert  JA.  Medicinal use of marijuana—polling results.  N Engl J Med. 2013;368(22):e30.PubMedGoogle ScholarCrossref
14.
Hoffmann  DE, Weber  E.  Medical marijuana and the law.  N Engl J Med. 2010;362(16):1453-1457.PubMedGoogle ScholarCrossref
15.
Razdan  RK.  Structure-activity relationships in cannabinoids.  Pharmacol Rev. 1986;38(2):75-149.PubMedGoogle Scholar
16.
Devane  WA, Dysarz  FA  III, Johnson  MR, Melvin  LS, Howlett  AC.  Determination and characterization of a cannabinoid receptor in rat brain.  Mol Pharmacol. 1988;34(5):605-613.PubMedGoogle Scholar
17.
Compton  DR, Rice  KC, De Costa  BR,  et al.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.  J Pharmacol Exp Ther. 1993;265(1):218-226.PubMedGoogle Scholar
18.
McAllister  SD, Glass  M.  CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.  Prostaglandins Leukot Essent Fatty Acids. 2002;66(2-3):161-171.PubMedGoogle ScholarCrossref
19.
Martin  BR, Wiley  JL.  Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.  J Support Oncol. 2004;2(4):305-314.PubMedGoogle Scholar
20.
Basu  S, Ray  A, Dittel  BN.  Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses.  J Immunol. 2011;187(11):5720-5732.PubMedGoogle ScholarCrossref
21.
Mechoulam  R, Peters  M, Murillo-Rodriguez  E, Hanus  LO.  Cannabidiol—recent advances.  Chem Biodivers. 2007;4(8):1678-1692.PubMedGoogle ScholarCrossref
22.
Jaeger  W, Benet  LZ, Bornheim  LM.  Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes.  Xenobiotica. 1996;26(3):275-284.PubMedGoogle ScholarCrossref
23.
Karniol  IG, Shirakawa  I, Kasinski  N, Pfeferman  A, Carlini  EA.  Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man.  Eur J Pharmacol. 1974;28(1):172-177.PubMedGoogle ScholarCrossref
24.
Mechoulam  R, Parker  LA.  The endocannabinoid system and the brain.  Annu Rev Psychol. 2013;64:21-47.PubMedGoogle ScholarCrossref
25.
Himmi  T, Dallaporta  M, Perrin  J, Orsini  JC.  Neuronal responses to delta 9-tetrahydrocannabinol in the solitary tract nucleus.  Eur J Pharmacol. 1996;312(3):273-279.PubMedGoogle ScholarCrossref
26.
Parker  LA, Kwiatkowska  M, Mechoulam  R.  Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting.  Physiol Behav. 2006;87(1):66-71.PubMedGoogle ScholarCrossref
27.
Kris  MG, Hesketh  PJ, Somerfield  MR,  et al; American Society of Clinical Oncology.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.  J Clin Oncol. 2006;24(18):2932-2947.PubMedGoogle ScholarCrossref
28.
Todaro  B.  Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting.  J Natl Compr Canc Netw. 2012;10(4):487-492.PubMedGoogle Scholar
29.
Tramèr  MR, Carroll  D, Campbell  FA, Reynolds  DJM, Moore  RA, McQuay  HJ.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.  BMJ. 2001;323(7303):16-21.PubMedGoogle ScholarCrossref
30.
Ben Amar  M.  Cannabinoids in medicine: a review of their therapeutic potential.  J Ethnopharmacol. 2006;105(1-2):1-25.PubMedGoogle ScholarCrossref
31.
Plasse  TF, Gorter  RW, Krasnow  SH, Lane  M, Shepard  KV, Wadleigh  RG.  Recent clinical experience with dronabinol.  Pharmacol Biochem Behav. 1991;40(3):695-700.PubMedGoogle ScholarCrossref
32.
Lane  M, Vogel  CL, Ferguson  J,  et al.  Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting.  J Pain Symptom Manage. 1991;6(6):352-359.PubMedGoogle ScholarCrossref
33.
Meiri  E, Jhangiani  H, Vredenburgh  JJ,  et al.  Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.  Curr Med Res Opin. 2007;23(3):533-543.PubMedGoogle ScholarCrossref
34.
Galli  JA, Sawaya  RA, Friedenberg  FK.  Cannabinoid hyperemesis syndrome.  Curr Drug Abuse Rev. 2011;4(4):241-249.PubMedGoogle ScholarCrossref
35.
Wallace  EA, Andrews  SE, Garmany  CL, Jelley  MJ.  Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm.  South Med J. 2011;104(9):659-664.PubMedGoogle ScholarCrossref
36.
Manzanares  J, Julian  M, Carrascosa  A.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.  Curr Neuropharmacol. 2006;4(3):239-257.PubMedGoogle ScholarCrossref
37.
Fine  PG, Rosenfeld  MJ.  The endocannabinoid system, cannabinoids, and pain.  Rambam Maimonides Med J. 2013;4(4):e0022.PubMedGoogle ScholarCrossref
38.
Facci  L, Dal Toso  R, Romanello  S, Buriani  A, Skaper  SD, Leon  A.  Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.  Proc Natl Acad Sci U S A. 1995;92(8):3376-3380.PubMedGoogle ScholarCrossref
39.
Ibrahim  MM, Porreca  F, Lai  J,  et al.  CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.  Proc Natl Acad Sci U S A. 2005;102(8):3093-3098.PubMedGoogle ScholarCrossref
40.
Abrams  DI, Guzman  M.  Cannabis in cancer care.  Clin Pharmacol Ther. 2015;97(6):575-586.PubMedGoogle ScholarCrossref
41.
Walker  JM, Strangman  NM, Huang  SM.  Cannabinoids and pain.  Pain Res Manag. 2001;6(2):74-79.PubMedGoogle ScholarCrossref
42.
Noyes  R  Jr, Brunk  SF, Baram  DA, Canter  A.  Analgesic effect of delta-9-tetrahydrocannabinol.  J Clin Pharmacol. 1975;15(2-3):139-143.PubMedGoogle ScholarCrossref
43.
Noyes  R  Jr, Brunk  SF, Avery  DA, Canter  AC.  The analgesic properties of delta-9-tetrahydrocannabinol and codeine.  Clin Pharmacol Ther. 1975;18(1):84-89.PubMedGoogle ScholarCrossref
44.
Portenoy  RK, Ganae-Motan  ED, Allende  S,  et al.  Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.  J Pain. 2012;13(5):438-449.PubMedGoogle ScholarCrossref
45.
Johnson  JR, Burnell-Nugent  M, Lossignol  D, Ganae-Motan  ED, Potts  R, Fallon  MT.  Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.  J Pain Symptom Manage. 2010;39(2):167-179.PubMedGoogle ScholarCrossref
46.
Di Marzo  V, Bifulco  M, De Petrocellis  L.  The endocannabinoid system and its therapeutic exploitation.  Nat Rev Drug Discov. 2004;3(9):771-784.PubMedGoogle ScholarCrossref
47.
Bowles  DW, O’Bryant  CL, Camidge  DR, Jimeno  A.  The intersection between cannabis and cancer in the United States.  Crit Rev Oncol Hematol. 2012;83(1):1-10.PubMedGoogle ScholarCrossref
48.
Pisanti  S, Malfitano  AM, Grimaldi  C,  et al.  Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.  Best Pract Res Clin Endocrinol Metab. 2009;23(1):117-131.PubMedGoogle ScholarCrossref
49.
McKallip  RJ, Nagarkatti  M, Nagarkatti  PS.  Δ-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.  J Immunol. 2005;174(6):3281-3289.PubMedGoogle ScholarCrossref
50.
Chakravarti  B, Ravi  J, Ganju  RK.  Cannabinoids as therapeutic agents in cancer: current status and future implications.  Oncotarget. 2014;5(15):5852-5872.PubMedGoogle ScholarCrossref
51.
Munson  AE, Harris  LS, Friedman  MA, Dewey  WL, Carchman  RA.  Antineoplastic activity of cannabinoids.  J Natl Cancer Inst. 1975;55(3):597-602.PubMedGoogle Scholar
52.
Massi  P, Vaccani  A, Ceruti  S, Colombo  A, Abbracchio  MP, Parolaro  D.  Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.  J Pharmacol Exp Ther. 2004;308(3):838-845.PubMedGoogle ScholarCrossref
53.
Sánchez  C, de Ceballos  ML, Gomez del Pulgar  T,  et al.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.  Cancer Res. 2001;61(15):5784-5789.PubMedGoogle Scholar
54.
Qamri  Z, Preet  A, Nasser  MW,  et al.  Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.  Mol Cancer Ther. 2009;8(11):3117-3129.PubMedGoogle ScholarCrossref
55.
Guzmán  M, Duarte  MJ, Blázquez  C,  et al.  A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.  Br J Cancer. 2006;95(2):197-203.PubMedGoogle ScholarCrossref
56.
Joy  JE, Watson  SJ, Benson  JA, eds.  Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academies Press; 1999.
57.
Sutton  IR, Daeninck  P.  Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain.  J Support Oncol. 2006;4(10):531-535.PubMedGoogle Scholar
58.
Volkow  ND, Baler  RD, Compton  WM, Weiss  SRB.  Adverse health effects of marijuana use.  N Engl J Med. 2014;370(23):2219-2227.PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    The Proper Scientific Term is Cannabis
    Duke Rodriguez | CEO and President, Ultra Health
    Thank you for writing about cannabis. I am concerned as to your use of the word \"marijuana\", especially in a scientific journal. Cannabis is the proper respectful and scientific term. The word \"marijuana\" or “marihuana” is an emotional, pejorative term (for many racially offensive) that has played a key role in creating a negative stigma with regard to the study and discovery of cannabis. Language is important because it defines our ideas, particularly in science. Simply inserting the word \"medical\" before marijuana is akin to referring to opioids as medical heroin. Research around the world (including published works by renowned scientist, Dr. Raphael Mechoulam, Hebrew University) properly frame the discussion with the appropriate terms such as 'cannabis', 'medical grade cannabis', or 'medical cannabis'. Continuing to use the \"M\" word (marijuana) only further trivializes the discovery and meaningful research being shared.
    CONFLICT OF INTEREST: None Reported
    READ MORE
    Review
    May 2016

    Medical Marijuana Use in Oncology: A Review

    Author Affiliations
    • 1Medical student at University of Massachusetts Medical School, Worcester
    • 2Program in Women’s Oncology, Women and Infants’ Hospital, Alpert Medical School of Brown University, Providence, Rhode Island
    JAMA Oncol. 2016;2(5):670-675. doi:10.1001/jamaoncol.2016.0155
    Abstract

    Importance  Medicinal marijuana use is currently legal in 23 states and the District of Columbia. As more states approve marijuana use for medical indications, physicians will be asked by their patients for more information regarding the risks and benefits of use. This article reviews the history, adverse effects, and proposed mechanisms of action of marijuana and summarizes the available literature regarding symptom relief and therapeutic value in patients with cancer.

    Observations  Marijuana in oncology may have potential for use as an antiemetic, for refractory cancer pain, and as an antitumor agent. However, much of the data are based on animal data, small trials, or are outdated.

    Conclusions and Relevance  More research is needed in all areas related to the therapeutic use of marijuana in oncology.

    ×